Skip to main
BTMD

Biote Corp (BTMD) Stock Forecast & Price Target

Biote Corp (BTMD) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Biote is facing pandemic-related risks that could potentially disrupt its operations and harm revenue. Additionally, with a business model that is subject to wage increases and other inflationary pressures, the company may struggle to pass on price increases to patients without negatively impacting business metrics. Furthermore, its limited operating history poses risks for potential production increases and future growth.

Bears say

Biote is experiencing challenges with acquisitions and retention of new clinics, as well as a slowdown in new clinic productivity due to a recall of certain hormone pellets, resulting in lower procedure revenues and a decrease in net income. The company also faces intense competition and risks associated with expanding into new markets, regulatory compliance, and dependence on key personnel and outsourcing facilities. These factors, coupled with ongoing legal expenses, lead to a negative outlook for the stock.

Biote Corp (BTMD) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biote Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biote Corp (BTMD) Forecast

Analysts have given Biote Corp (BTMD) a Buy based on their latest research and market trends.

According to 3 analysts, Biote Corp (BTMD) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biote Corp (BTMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.